All‐ Trans ‐Retinoic Acid‐Adjuvanted mRNA Vaccine Induces Mucosal Anti‐Tumor Immune Responses for Treating Colorectal Cancer
Advanced Science · 2024
DOI: 10.1002/advs.202309770 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Wei Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Beijing National Laboratory for Molecular Sciences, CAS Key Laboratory of Colloid, Interface and Chemical Thermodynamics, Institute of Chemistry, Chi…. Hauptthemen laut MEDLINE: Tretinoin, Colorectal Neoplasms, Cancer Vaccines. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Messenger RNA (mRNA) cancer vaccines are a new class of immunotherapies that can activate the immune system to recognize and destroy cancer cells. However, their effectiveness in treating colorectal cancer located on the mucosal surface of the gut is limited due to the insufficient activation of mucosal immune response and inadequate infiltration of cytotoxic T cells into tumors. To address this issue, a new mRNA cancer vaccine is developed that can stimulate mucosal immune responses in the gut by co‐delivering all‐ trans ‐retinoic acid (ATRA) and mRNA using lipid nanoparticle (LNP). The incorporation of ATRA has not only improved the mRNA transfection efficiency of LNP but also induced high expression of gut‐homing receptors on vaccine‐activated T cells. Additionally, the use of LNP improves the aqueous solubility of ATRA, eliminating the need for toxic solvents to administer ATRA. Upon intramuscular injections, ATRA‐adjuvanted mRNA‐LNP significantly increase the infiltration of antigen‐specific, cytotoxic T cells in the lamina propria of the intestine, mesenteric lymph nodes, and orthotopic colorectal tumors, resulting in significantly improved tumor inhibition and prolonged animal survival compared to conventional mRNA‐LNP without ATRA. Overall, this study provides a promising approach for improving the therapeutic efficacy of mRNA cancer vaccines against colorectal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing National Laboratory for Molecular Sciences, CAS Key Laboratory of Colloid, Interface and Chemical Thermodynamics, Institute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, China.
- University of Chinese Academy of Sciences, Beijing, 100049, China.
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
- Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
ORCID-Profile: Xueguang Lu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, W., Li, Y., Li, J., Meng, J., Jiang, Z., Yang, C., Wen, Y., Liu, S., Cheng, X., Mi, S., Zhao, Y., Miao, L., & Lu, X. (2024). All‐ Trans ‐Retinoic Acid‐Adjuvanted mRNA Vaccine Induces Mucosal Anti‐Tumor Immune Responses for Treating Colorectal Cancer. Advanced Science. https://doi.org/10.1002/advs.202309770
Vancouver
Li W, Li Y, Li J, Meng J, Jiang Z, Yang C, et al. All‐ Trans ‐Retinoic Acid‐Adjuvanted mRNA Vaccine Induces Mucosal Anti‐Tumor Immune Responses for Treating Colorectal Cancer. Advanced Science. 2024. doi:10.1002/advs.202309770
BibTeX
@article{Li2024,
author = {Li, Wei and Li, Yijia and Li, Jingjiao and Meng, Junli and Jiang, Ziqiong and Yang, Chen and Wen, Yixing and Liu, Shuai and Cheng, Xingdi and Mi, Shiwei and Zhao, Yuanyuan and Miao, Lei and Lu, Xueguang},
title = {All‐ Trans ‐Retinoic Acid‐Adjuvanted mRNA Vaccine Induces Mucosal Anti‐Tumor Immune Responses for Treating Colorectal Cancer},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202309770}
}
EUVIMED